Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pridopidine activates neuroprotective pathways impaired in Huntington Disease.
Geva M, Kusko R, Soares H, Fowler KD, Birnberg T, Barash S, -Wagner AM, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, Zeskind B, Grossman I, Hayden MR. Geva M, et al. Among authors: kusko r. Hum Mol Genet. 2016 Sep 15;25(18):3975-3987. doi: 10.1093/hmg/ddw238. Epub 2016 Jul 27. Hum Mol Genet. 2016. PMID: 27466197 Free PMC article.
A primer on applying AI synergistically with domain expertise to oncology.
Kim J, Kusko R, Zeskind B, Zhang J, Escalante-Chong R. Kim J, et al. Among authors: kusko r. Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188548. doi: 10.1016/j.bbcan.2021.188548. Epub 2021 Apr 24. Biochim Biophys Acta Rev Cancer. 2021. PMID: 33901609 Free article. Review.
Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.
Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR. Kusko R, et al. Mol Neurodegener. 2018 May 21;13(1):25. doi: 10.1186/s13024-018-0259-3. Mol Neurodegener. 2018. PMID: 29783994 Free PMC article.
Drug repurposing from the perspective of pharmaceutical companies.
Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, Kusko R, Zeskind B, Risso S, Kagan E, Papapetropoulos S, Grossman I, Laifenfeld D. Cha Y, et al. Among authors: kusko r. Br J Pharmacol. 2018 Jan;175(2):168-180. doi: 10.1111/bph.13798. Epub 2017 May 18. Br J Pharmacol. 2018. PMID: 28369768 Free PMC article. Review.
Letter to the Editor response: Nygaard et al.
Towfic F, Kusko R, Zeskind B. Towfic F, et al. Among authors: kusko r. Biostatistics. 2017 Apr 1;18(2):197-199. doi: 10.1093/biostatistics/kxw031. Biostatistics. 2017. PMID: 27780809 Free PMC article.
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, Boothman DA. Huang X, et al. Among authors: kusko r. Cancer Cell. 2016 Dec 12;30(6):940-952. doi: 10.1016/j.ccell.2016.11.006. Cancer Cell. 2016. PMID: 27960087 Free PMC article.
42 results